Bio-Rad Laboratories (BIO.B) Financials

Bio-Rad Laboratories’ Q2 2026 results show improving earnings but uneven underlying performance. Revenue increased to $651.0 million from $592.1 million in Q1 2026, although it was essentially flat compared with $651.6 million in Q2 2025. The company’s revenue remains below levels reported in earlier periods, including $730.2 million in Q4 2022 and $681.1 million in Q2 2023.

Gross profit was $345.8 million, producing a gross margin of approximately 53.1%, slightly above the 53.0% margin in Q2 2025. However, operating income declined to $72.6 million from $77.1 million a year earlier, and the operating margin narrowed to about 11.2% from 11.8%. Operating expenses were broadly stable, but revenue growth has not been strong enough to generate consistent operating leverage.

Reported net income improved to $371.4 million, or $13.85 per diluted share, compared with $317.8 million, or $11.67 per diluted share, in Q2 2025. However, $481.6 million of other income accounted for most of the company’s pre-tax earnings. This contrasts with the $711.6 million of other expense recorded in Q1 2026, when Bio-Rad posted a $527.1 million net loss. The sharp swings indicate that investment-related and other non-operating items are having a substantial effect on reported earnings.

• Q2 earnings rebounded sharply. Net income rose approximately 17% year over year and reversed the large loss reported in Q1 2026.
• Liquidity remains strong. Bio-Rad held $517.0 million in cash and $1.10 billion in short-term investments at June 30, 2026, providing roughly $1.62 billion of immediately available financial assets.
• The balance sheet is conservatively financed. Total debt was approximately $1.20 billion, compared with $7.17 billion of shareholders’ equity. The company also had a current ratio of about 3.1, indicating substantial coverage of short-term obligations.
• Long-term investment holdings continue to provide financial flexibility. Long-term investments increased to $5.72 billion from $5.06 billion in Q3 2025 and $5.58 billion in Q2 2025.
• Share repurchases continue to support per-share results. Bio-Rad repurchased $31.5 million of common stock in Q2 2026, following $47.8 million in Q1 and $53.4 million in Q3 2025.
• Revenue improved sequentially but remains stagnant year over year. Q2 revenue was 10% higher than Q1 2026, but was virtually unchanged from Q2 2025 and below several earlier quarterly levels.
• Operating profitability is positive but inconsistent. Operating income was positive in Q1 and Q2 2026, but the company reported operating losses in Q4 2025 despite generating substantial revenue.
• Investment activity is a recurring source of cash-flow volatility. Bio-Rad purchased $184.2 million of investments and received $148.5 million from investment sales in Q2 2026, producing a net investing cash outflow of $66.7 million.
• Operating cash flow deteriorated materially in Q2. Net cash from operating activities was negative $131.4 million, compared with positive $108.1 million in Q1 2026 and negative $0.9 million in Q2 2025.
• Reported earnings remain highly dependent on non-operating gains. The company’s Q2 profit was much larger than its operating income because of other income, while Q1 2026 and several 2025 periods were burdened by large other expenses.

Bio-Rad’s balance sheet continues to be a major strength. Total assets rose to $10.25 billion from $9.79 billion in Q1 2026, while total liabilities were $3.08 billion. Nevertheless, investment holdings represent a very large portion of total assets, making reported earnings and equity sensitive to market valuations. Accumulated other comprehensive loss also widened to $271.3 million from $154.1 million a year earlier.

For investors, the key issue is whether Bio-Rad can translate the Q2 revenue improvement into steadier operating cash generation. The company has ample liquidity and modest leverage, but the recent pattern of weak or negative operating cash flow and large swings in other income suggests that headline net income may not fully reflect recurring business performance. Comparisons should also be made carefully because several historical figures in the supplied data are marked as restated or calculated.